Two prospective phase 2 studies in individuals with relapsed or refractory AL amyloidosis statement that daratumumab monotherapy induced a VGPR or better hematologic response in 47% and 86% of individuals, respectively
Two prospective phase 2 studies in individuals with relapsed or refractory AL amyloidosis statement that daratumumab monotherapy induced a VGPR or better […]